TherapeuticsMD (TXMD) Misses Q3 EPS by 9c

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($0.05), $0.09 worse than the analyst estimate of $0.04.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• JPMorgan Upgrades Kolmar Korea Co Ltd (161890:KS) to Overweight
• Samvardhana Motherson International (MOTHERSO:IN) PT Raised to INR170 at JPMorgan